Navigation Links
Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment

Tallahassee Dermatologist Encourages Regular Skin Examinations

TALLAHASSEE, Fla., Sept. 12 /PRNewswire/ -- Once every two hours a Florida resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease this alarming statistic, and increase the likelihood that local residents diagnosed with this deadliest type of skin cancer will survive.

"Staying out of the sun or protecting your skin from harmful ultraviolet rays is the best defense against skin cancer, but it's equally important to have your skin examined at least once a year by a board-certified dermatologist, especially if you have any moles that are irregular in shape or have recently appeared or changed in size, shape or color," said Dr. Armand Cognetta, medical co-director of the nationwide trial of Dermatology Associates of Tallahassee. "Early detection of suspicious moles is the key to preventing melanoma."

When melanoma is caught in its early stages, it's almost always curable.

Risk factors for melanoma include:

* Sunlight, or too much exposure to ultraviolet radiation

* Presence of many moles and/or large moles (>6mm)

* Fair skin, freckling, light eyes, or natural red or blond hair

* Family history of melanoma

* Past personal history of melanoma

Traditionally, dermatologists have relied on their own eyes and judgment in deciding whether to remove a suspicious mole.

Dermatology Associates of Tallahassee is participating in a nationwide patient trial to test an investigational medical technology called MelaFind(R), designed to assist physicians in the early diagnosis of melanoma.

MelaFind is a non-invasive hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions (moles). MelaFind then analyzes the images in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

"We encourage patients to come in for skin exams in general, especially during the summer months when people tend to spend a lot of time outdoors in the sun," said Dr. Cognetta.

If you think you have a mole that may be cancerous, and would like to have it examined, please contact Dermatology Associates of Tallahassee at 850-877-4134. You may also be eligible to participate in the MelaFind trial.

About Dermatology Associates of Tallahassee

Dermatology Associates of Tallahassee is proud to have served the community for over 20 years. We are your skin cancer management professionals providing examination and treatment of skin lesions and disease. We have seven dermatologists on staff, and pride our self in offering complete skin care management, Mohs micrographic surgery, Puva light therapy, and radiation treatment. Dr. Cognetta is the medical co-director of the MelaFind trial and is only one of forty directors of the American College of Mohs Micrographic Surgery fellowship. Dr. Cognetta has devoted and built his practice in skin cancer detection and treatment over the last seventeen years.

Media Contact:

Erich Sandoval, Lazar Partners

Tel: (212) 867-1762

SOURCE Dermatology Associates of Tallahassee
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial Services, ... preparation services, is providing an update on a charitable event that began earlier ... is a locally recognized nonprofit that provides shelter and care for animals seeking ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
Breaking Medicine News(10 mins):